The US is experiencing an epidemic of HPV + oropharyngeal cancers (OPC), the rates and burden of which now exceed that for cervical cancer. Immunotherapy targeting programmed death 1 (PD-1) on tumor-infiltrating lymphocytes and/or its ligand PD-L1 on tumor cells, which was effective in...
From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Dallas event is provided here. The purpose of...
Advances in Cancer Immunotherapy™ Post-Program Webinar 1 (Dallas).mp4
T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantigens derived from somatic mutations. However, few neoantigens per patient are able to...
Voices of Immunotherapy is a video library presented by Cancer Support Community (CSC). Here, patients and healthcare professionals discuss their experiences with immunotherapy. Click here to browse the entire video library or click on a link below for the specific video: Immunotherapy...
On July 24, 2019, leading experts in cancer immunotherapy presented an overview of the publication " The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) " at a live webinar. The recorded webinar...
2 attachments
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in...
Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these...
The immunogenomic changes triggered by concurrent chemoradiation therapy (CCRT), a standard neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC), are unknown. The authors aimed to analyze the early immunogenomic changes in ESCC induced by CCRT and to correlate...
With cutting-edge data regularly emerging from conferences and new FDA approvals, keeping updated with the latest cancer immunotherapy research is an arduous task for a practicing clinician. To complement and expand upon the live Advances in Cancer Immunotherapy™ (ACI) programs, SITC is proud to...
On July 24, 2019, leading experts in cancer immunotherapy presented an overview of the recently published SITC Cancer Immunotherapy Guidelines – Squamous Cell Carcinoma of the Head and Neck (HNSCC) at a live webinar. This FREE CME-, CNE-, CPE-certified webinar provided a chance for...
07-24-2019 | 15:00 - 16:00 ET
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us